Sunitinib

Generic Name
Sunitinib
Brand Names
Sutent, Sunitinib Accord
Drug Type
Small Molecule
Chemical Formula
C22H27FN4O2
CAS Number
557795-19-4
Unique Ingredient Identifier
V99T50803M
Background

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

Indication

Sunitinib is indicated for the following conditions:

Associated Conditions
Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
Associated Therapies
-
Clinical Trials
Related News

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Phase 3
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: pazopanib
Drug: sunitinib
First Posted Date
2010-02-08
Last Posted Date
2017-04-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
169
Registration Number
NCT01064310
Locations
🇬🇧

Novartis Investigative Site, Wolverhampton, United Kingdom

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

First Posted Date
2010-02-03
Last Posted Date
2022-08-05
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
16
Registration Number
NCT01061411
Locations
🇳🇱

Academ Zienkenhuis Bij De University, Amsterdam, Netherlands

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

and more 1 locations

Evaluation of Patients With Bulky GIST Using Sunitinib

Not Applicable
Terminated
Conditions
Tumor
Interventions
Drug: Sunitinib
Procedure: Surgery
First Posted Date
2010-01-22
Last Posted Date
2016-09-22
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
5
Registration Number
NCT01054911
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Phase 2
Terminated
Conditions
Urothelial Carcinoma
Bladder Cancer
Interventions
Drug: Sunitinib
First Posted Date
2010-01-06
Last Posted Date
2017-06-28
Lead Sponsor
University of Michigan
Target Recruit Count
7
Registration Number
NCT01042795
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Sunitinib in Metastatic Renal Cancer

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Sunitinib
First Posted Date
2009-12-18
Last Posted Date
2014-12-23
Lead Sponsor
Istituto Clinico Humanitas
Target Recruit Count
25
Registration Number
NCT01034878
Locations
🇮🇹

Istituto Clinco Humanitas, Rozzano, Milano, Italy

Cost Effectiveness Of Sunitinib In Central America And Caribbean

Terminated
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Drug: Sunitinib
First Posted Date
2009-12-17
Last Posted Date
2012-04-19
Lead Sponsor
Pfizer
Target Recruit Count
4
Registration Number
NCT01033981
Locations
🇵🇦

Pfizer Investigational Site, Panama City, Panama

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

First Posted Date
2009-12-04
Last Posted Date
2019-06-25
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
43
Registration Number
NCT01026337
Locations
🇺🇸

Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: BIBF 1120
Drug: sunitinib
First Posted Date
2009-12-03
Last Posted Date
2021-07-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
99
Registration Number
NCT01024920
Locations
🇵🇱

Onco.Cent. - Instit. of Maria Sklodowskiej-Curie, Warszawa, Poland

🇭🇺

University of Pecs Medical School, Dept. of Oncotherapy, Pecs, Hungary

🇵🇱

Ziemia Lubelska Oncological Center, Lublin, Lublin, Poland

and more 12 locations

Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 2
Completed
Conditions
Kidney Cancer
First Posted Date
2009-12-02
Last Posted Date
2013-08-12
Lead Sponsor
Barts and the London School of Medicine and Dentistry
Target Recruit Count
43
Registration Number
NCT01024205
Locations
🇬🇧

Orchid Clinical Trials Group at Barts and the London School of Medicine and Dentistry, London, England, United Kingdom

Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI

Phase 2
Completed
Conditions
Adenocarcinoma
Interventions
Drug: Sunitinib
Drug: Placebo
First Posted Date
2009-11-25
Last Posted Date
2014-05-14
Lead Sponsor
PD Dr Markus Möhler
Target Recruit Count
91
Registration Number
NCT01020630
Locations
🇩🇪

Helios Klinikum Berlin-Buch, Berlin, Germany

🇩🇪

Martin-Luther-Universität Halle-Wittenberg, Halle, Germany

🇩🇪

Klinikum Weiden, Weiden, Germany

and more 13 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy